MP drop-in event in the House of Commons

MP drop-in, House of Commons on 25th February 2019

First and foremost we would like to thank MDUK and SMAUK for organising the drop-in event for MPs, particularly at such short notice.

On more personal note, despite the efforts put in by the organising parties, the low attendance number has left me disappointed and frustrated regarding our fight for SPINRAZA FOR ALL. A number of MPs came into the room, the majority just to have their photo snapped in front of the MDUK and SMA UK campaign board, obviously self-publicity.

Barely a handful of MPs showed an interest or actually spoke to some of us with genuine concern/support! I would like to say a personal thank you to Eleanor Smith, Mary Glindon and Will Quince MPs. Unfortunately, my local member was amongst the many “no show” invitees.

With too much apathy surrounding approval here… the emphasis needs to be our responsibility, or to encourage any representatives, families, friends, colleagues, to attend the Manchester protest Spinraza For All next Wednesday.

Financial assistance can be provided – many thanks to two thoughtful and considerate Anonymous Donors 🙂

Please feel free to contact me if you have any questions at all: dawn.wilbur@treatsma.uk.

Happy days!

Dawn (TreatSMA type 2/3 representative)

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more